Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd banner

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 39.89 CNY 2.26% Market Closed
Market Cap: ¥30.7B

EV/FCFF

77.4
Current
87%
More Expensive
vs 3-y average of 41.3

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
77.4
=
Enterprise Value
¥27.1B
/
Free Cash Flow to Firm
¥342.5m

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
77.4
=
Enterprise Value
¥27.1B
/
Free Cash Flow to Firm
¥342.5m

Valuation Scenarios

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is trading above its 3-year average

If EV/FCFF returns to its 3-Year Average (41.3), the stock would be worth ¥21.29 (47% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-63%
Maximum Upside
No Upside Scenarios
Average Downside
56%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 77.4 ¥39.89
0%
3-Year Average 41.3 ¥21.29
-47%
5-Year Average 36.3 ¥18.74
-53%
Industry Average 30.7 ¥15.83
-60%
Country Average 28.8 ¥14.85
-63%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
30.7B CNY 77.4 14.4
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 140.4 39
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 29.1 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 34.8 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 19 19.5
US
Merck & Co Inc
NYSE:MRK
274.6B USD 24.8 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 42.2 11.1
US
Pfizer Inc
NYSE:PFE
149.3B USD 21.8 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 11.6 16.4

Market Distribution

Higher than 77% of companies in China
Percentile
77th
Based on 4 731 companies
77th percentile
77.4
Low
0 — 14.5
Typical Range
14.5 — 57
High
57 —
Distribution Statistics
China
Min 0
30th Percentile 14.5
Median 28.8
70th Percentile 57
Max 307 555.7

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View

Market Cap
30.7B CNY
Industry
Pharmaceuticals

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.

Intrinsic Value
37.33 CNY
Overvaluation 6%
Intrinsic Value
Price ¥39.89
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett